share_log

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)

Exicure | SC 13D/A：超过5%持股股东披露文件(修正)-DGP Co., Ltd.(35.4%),CBI USA, Inc.(9.5%)
美股sec公告 ·  07/02 18:15
Moomoo AI 已提取核心信息
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a recent Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated June 28, 2024, is an amendment (Amendment No. 12) to a series of previous amendments and the initial Schedule 13D filed on June 1, 2022. This latest amendment involves two reporting persons, CBI USA, Inc., and DGP Co., Ltd., both of which have disclosed significant ownership stakes in Exicure. CBI USA, Inc., a Delaware-based entity, reported owning 818,299 shares, representing 9.5% of the company, while DGP Co., Ltd., based in the Republic of Korea, reported a substantial holding of 3,060,000 shares, amounting to 35.4% of Exicure. The amendment also details contractual arrangements, including an extension of the closing date for the balance of the DGP Sale to July 31, 2024, and an extension of the settlement date for a Stock Loan to December 31, 2024. The filing was certified by Kyungwon Oh, the Chief Executive Officer of both CBI USA, Inc. and DGP Co., Ltd.
Exicure, Inc., a biotechnology company traded on NASDAQ under the ticker XCUR, has been the subject of a recent Schedule 13D/A filing with the United States Securities and Exchange Commission (SEC). The filing, dated June 28, 2024, is an amendment (Amendment No. 12) to a series of previous amendments and the initial Schedule 13D filed on June 1, 2022. This latest amendment involves two reporting persons, CBI USA, Inc., and DGP Co., Ltd., both of which have disclosed significant ownership stakes in Exicure. CBI USA, Inc., a Delaware-based entity, reported owning 818,299 shares, representing 9.5% of the company, while DGP Co., Ltd., based in the Republic of Korea, reported a substantial holding of 3,060,000 shares, amounting to 35.4% of Exicure. The amendment also details contractual arrangements, including an extension of the closing date for the balance of the DGP Sale to July 31, 2024, and an extension of the settlement date for a Stock Loan to December 31, 2024. The filing was certified by Kyungwon Oh, the Chief Executive Officer of both CBI USA, Inc. and DGP Co., Ltd.
生物技术公司exicure在纳斯达克交易所上市，股票代码为XCUR，最近成为美国证券交易委员会（SEC）一份最新的13D / A申报文件的对象。该申报文件日期为2024年6月28日，是对一系列之前的修订和于2022年6月1日提交的首份13D申报文件的第12次修订。这份最新的修订涉及两个报告人，分别是总部位于特拉华州的CBI USA， Inc.，和总部位于韩国的DGP Co.， Ltd.，两者均透露拥有Exicure的重要持股。总部位于特拉华州的CBI USA，Inc.报告拥有818,299股股票，占公司的9.5％，而总部位于韩国的DGP Co.，Ltd.报告的持有量则为3,060,000股，占...展开全部
生物技术公司exicure在纳斯达克交易所上市，股票代码为XCUR，最近成为美国证券交易委员会（SEC）一份最新的13D / A申报文件的对象。该申报文件日期为2024年6月28日，是对一系列之前的修订和于2022年6月1日提交的首份13D申报文件的第12次修订。这份最新的修订涉及两个报告人，分别是总部位于特拉华州的CBI USA， Inc.，和总部位于韩国的DGP Co.， Ltd.，两者均透露拥有Exicure的重要持股。总部位于特拉华州的CBI USA，Inc.报告拥有818,299股股票，占公司的9.5％，而总部位于韩国的DGP Co.，Ltd.报告的持有量则为3,060,000股，占Exicure的35.4％。该修订还详细说明了合同安排，包括将DGP Sale的尾款截止日期延长到2024年7月31日，以及将一项股票贷款的结算日期延长到2024年12月31日。该申报文件由CBI USA，Inc.和DGP Co.，Ltd.的首席执行官Kyungwon Oh签署认证。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息